Clinical Effects of Prebiotics in Pediatric Population

Rok Orel1, Lea Vodušek Reberšak

  • 1University Medical Centre, Ljubljana, University Children's Hospital; Ljubljana, Slovenia. Correspondence to: Prof Rok Orel, University Children's Hospital, BohoriÃceva 20, 1000 Ljubljana, Slovenia. rok.orel@kclj.si.

Indian Pediatrics
|January 9, 2017
PubMed

Insights

Prebiotics show promise for treating pediatric constipation, poor weight gain, and eczema. However, more high-quality clinical trials are needed to confirm their efficacy and optimal use in children.

Area of Science:

  • Pediatric Gastroenterology
  • Microbiome Research
  • Nutritional Science

Background:

  • Prebiotics selectively promote beneficial gut microbes, impacting host health.
  • This review examines prebiotic use for common pediatric conditions.

Purpose of the Study:

  • To review current literature on the clinical effects of prebiotics in pediatric pathology.
  • To assess the efficacy of prebiotics in treating and preventing common childhood ailments.

Main Methods:

  • Searched MEDLINE, PubMed, UpToDate, and Cochrane databases up to September 2015.
  • Included only studies of adequate methodological quality.

Main Results:

  • Prebiotics show potential for treating constipation, poor weight gain in preterm infants, and eczema.
  • Evidence for prebiotic clinical efficacy in children is limited, with sparse data on specific types and doses.
  • Few randomized controlled trials exist for prebiotics in children, particularly older ones.

Conclusions:

  • Further large, well-designed, controlled trials are necessary.
  • Research should focus on commercially available prebiotic products.
  • Evidence is needed to guide healthcare providers on appropriate prebiotic use in pediatric conditions.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
586
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
304
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
405
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
818
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
343
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.0K